UPB
Upstream Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.34
+0.56%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.73
- Revenue estimate
- $522.5K
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.73
- EPS estimate
- -$0.78
- Revenue actual
- $773.0K
- Revenue estimate
- $561.4K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +4.1%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $23
- PT range
- $9.00 – $36
- Analysts
- 4
3 Buy1 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.78 | -$0.73 | Beat 6.41% | $773.0K |
| May 13, 2026 | -$0.74 | -$0.75 | Miss -1.18% | $1.0M |
| Mar 26, 2026 | -$0.73 | -$0.79 | Miss -8.22% | $668.0K |
| Nov 5, 2025 | -$0.78 | -$0.63 | Beat 19.23% | $683.0K |
| Mar 13, 2025 | -$0.56 | -$1.59 | Miss -183.93% | $613.0K |
| Nov 7, 2024 | -$0.54 | -$6.96 | Miss -1200.30% | $607.0K |
| Dec 31, 2023 | — | -$0.14 | — | $2.4M |
| Sep 30, 2023 | — | -$0.09 | — | $621.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026